DK1436012T3 - Polymerkonjugater af opioidantagonister - Google Patents
Polymerkonjugater af opioidantagonister Download PDFInfo
- Publication number
- DK1436012T3 DK1436012T3 DK02795531.9T DK02795531T DK1436012T3 DK 1436012 T3 DK1436012 T3 DK 1436012T3 DK 02795531 T DK02795531 T DK 02795531T DK 1436012 T3 DK1436012 T3 DK 1436012T3
- Authority
- DK
- Denmark
- Prior art keywords
- polymer
- pharmaceutical composition
- opioid
- conjugate
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Farmaceutisk sammensætning omfattende: et polymerkonjugat, eller et farmaceutisk acceptabelt salt deraf, omfattende en poly(ethylenglycol)polymer kovalent bundet til en opioidantagonist, hvori polymerens molekylevægt er mindre end 2000 Da, og en farmaceutisk acceptabel bærer, hvori polymerkonjugatet har strukturen hvori:
POLY er poly(ethylenglycol)polymeren X er en hydrolytisk stabil binding; Y er allyl; Z er H eller OH; og den stiplede linje repræsenterer en valgfri dobbeltbinding.
2. Farmaceutisk sammensætning ifølge krav 1, hvor opioidantagonisten er naloxon.
3. Farmaceutisk sammensætning ifølge krav 1, hvori den hydrolytisk stabile binding er valgt fra gruppen bestående af amid, amin, carbamat, ether, thioether og urinstof.
4. Farmaceutisk sammensætning ifølge krav 1, hvori polymerens molekylvægt er mindre end ca. 1000 Da.
5. Farmaceutisk sammensætning ifølge krav 1, hvori polymerens molekylvægt er mindre end ca. 800 Da.
6. Farmaceutisk sammensætning ifølge krav 1, hvori X er -NH-(CHR0)m-O- eller -NH-C(O)-(CHR0)m-O-, m eller n er 1-12 og hver Ro uafhængigt er H eller CrCe alkyl.
7. Farmaceutisk sammensætning ifølge krav 1, hvori X er et heteroatom.
8. Farmaceutisk sammensætning ifølge krav 1, der yderligere omfatter en opioidagonist.
9. Farmaceutisk sammensætning ifølge krav 8, hvori opioidagonisten er valgt fra gruppen bestående af alfentanil, bremazocin, buprenorphin, butorphanol, kodein, cyclazocin, dezocin, diacetylmorfin, dihydrokodein, fentanyl, hydrocodon, hydromorphon, levorphanol, meperidin (pethidin), methadon, morfin, nalbuphin, noscapin, oxycodon, oxymorphon, papaverin, pentazocin, pethidin, phenazocin, propiram, propoxyphen, sufentanil, thebain og tramadol.
10. Farmaceutisk sammensætning ifølge krav 1 til anvendelse til behandling af en bivirkning resulterende fra administrationen af en opioidagonist til et pattedyr.
11. Farmaceutisk sammensætning ifølge krav 10, hvori bivirkningen er valgt fra gruppen bestående af kvalme, forstoppelse og pruritus.
12. Farmaceutisk sammensætning ifølge krav 10, hvori den farmaceutiske sammensætning administreres oralt.
13. Farmaceutisk sammensætning ifølge krav 10, hvori den farmaceutiske sammensætning administreres sammen med opioidagonisten.
14. Farmaceutisk sammensætning ifølge krav 13, hvori polymerkonjugatet og opioidagonisten er formuleret i en enkelt doseringsenhed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33040001P | 2001-10-18 | 2001-10-18 | |
PCT/US2002/033325 WO2003032990A2 (en) | 2001-10-18 | 2002-10-18 | Polymer conjugates of opioid antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1436012T3 true DK1436012T3 (da) | 2018-01-22 |
Family
ID=23289594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15172363.2T DK2939696T3 (da) | 2001-10-18 | 2002-10-18 | Polymerkonjugater af opioidantagonister |
DK02795531.9T DK1436012T3 (da) | 2001-10-18 | 2002-10-18 | Polymerkonjugater af opioidantagonister |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15172363.2T DK2939696T3 (da) | 2001-10-18 | 2002-10-18 | Polymerkonjugater af opioidantagonister |
Country Status (15)
Country | Link |
---|---|
US (4) | US7056500B2 (da) |
EP (3) | EP2939696B1 (da) |
JP (2) | JP4814488B2 (da) |
KR (2) | KR101009309B1 (da) |
AU (1) | AU2002360284B2 (da) |
CA (1) | CA2463938C (da) |
CY (1) | CY1119906T1 (da) |
DK (2) | DK2939696T3 (da) |
ES (2) | ES2569262T3 (da) |
HK (1) | HK1215171A1 (da) |
LT (1) | LT1436012T (da) |
MX (1) | MXPA04003597A (da) |
PT (2) | PT2939696E (da) |
SI (2) | SI1436012T1 (da) |
WO (1) | WO2003032990A2 (da) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
MXPA02003176A (es) * | 1999-10-04 | 2002-09-30 | Shearwater Corp | Neuropeptidos estabilizados por polimero. |
KR101009309B1 (ko) | 2001-10-18 | 2011-01-18 | 넥타르 테라퓨틱스 | 아편양 길항제의 중합체 공액 |
ME00239B (me) * | 2002-01-18 | 2011-05-10 | Biogen Ma Inc | Polimerna jedinjenja polialkilena i njihova upotreba |
CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
BRPI0409133B8 (pt) * | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
CN1767830A (zh) * | 2003-04-08 | 2006-05-03 | 普罗热尼奇制药公司 | 外周阿片拮抗剂具体是甲基纳曲酮治疗肠易激综合征的用途 |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
US8637650B2 (en) | 2003-11-05 | 2014-01-28 | Genovoxx Gmbh | Macromolecular nucleotide compounds and methods for using the same |
AU2014280956B2 (en) * | 2003-12-16 | 2016-09-22 | Nektar Therapeutics | Chemically modified small molecules |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
ES2733764T3 (es) * | 2003-12-16 | 2019-12-02 | Nektar Therapeutics | Método para la preparación de oligo etilenglicol monodisperso |
US20050215710A1 (en) * | 2004-03-23 | 2005-09-29 | Gegg Colin V Jr | Chemically modified protein compositions and methods |
US7495098B2 (en) * | 2004-06-08 | 2009-02-24 | Mallinckrodt Inc | Extraction of alkaloids from opium |
US20090069363A1 (en) * | 2004-12-14 | 2009-03-12 | Shionogi & Co. Ltd. A Legal Entity Of Japan | Therapeutic Agent for Constipation |
EP1845989A1 (en) * | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
CN101466381B (zh) | 2006-04-21 | 2012-11-14 | 尼克塔治疗公司 | ***酮的立体选择性还原 |
EP2046393B1 (en) | 2006-05-26 | 2014-02-12 | Signature Therapeutics, Inc. | Controlled release of phenolic opioids |
CN101534827A (zh) * | 2006-11-07 | 2009-09-16 | 尼克塔治疗亚拉巴马公司 | 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药 |
BRPI0719305A2 (pt) * | 2006-11-22 | 2014-02-04 | Progenics Pharm Inc | (r)-n-estereoisômeros de análogos de 7,8-saturados-4,5-epóxi-morfinano |
WO2008101187A2 (en) * | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | Pro-drugs of peripheral phenolic opioid antagonists |
JP5615558B2 (ja) * | 2007-02-28 | 2014-10-29 | セリナ・セラピユーテイツクス・インコーポレーテツド | 活性ポリオキサゾリンおよびそれを含む組成物 |
US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
SI2134371T1 (sl) * | 2007-03-12 | 2015-04-30 | Nektar Therapeutics | Konjugati agonista oligomer-opioid |
WO2008121348A2 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
ES2540551T3 (es) | 2007-03-29 | 2015-07-10 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
JP2010522756A (ja) | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 結晶形およびその使用 |
EP2214672B1 (en) * | 2007-10-18 | 2012-10-17 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
WO2009099411A1 (en) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
JP2011519930A (ja) * | 2008-05-07 | 2011-07-14 | ネクター セラピューティクス | 末梢性オピオイドアンタゴニストの経口投与 |
JP5985824B2 (ja) | 2008-07-01 | 2016-09-06 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド受容体アンタゴニスト含有の粒子および使用方法 |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
CA2734333A1 (en) * | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
BR112012006069A8 (pt) * | 2009-09-18 | 2017-10-10 | Adolor Corp | Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto |
US9315860B2 (en) | 2009-10-26 | 2016-04-19 | Genovoxx Gmbh | Conjugates of nucleotides and method for the application thereof |
NZ702826A (en) | 2010-03-11 | 2016-08-26 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
CA2812649C (en) | 2010-09-30 | 2016-03-01 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
KR102016305B1 (ko) * | 2011-11-07 | 2019-08-30 | 넥타르 테라퓨틱스 | 오피오이드 작용제 화합물 및 진통제 화합물의 조성물, 투여형 및 공동 투여 |
US9795689B2 (en) * | 2012-09-11 | 2017-10-24 | University Of Massachusetts | Crosslinked polymer nano-assemblies and uses thereof |
PT2914599T (pt) | 2012-10-30 | 2018-01-08 | Nektar Therapeutics | Forma de sal sólida de alfa-6-mpeg6-o-hidroxicodona como agonistas opioides e suas utilizações |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
NZ724990A (en) * | 2014-04-28 | 2023-09-29 | Dimerx Inc | Pharmaceutically active dimers linked through phenolic hydroxyl groups |
AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
GB2545368B (en) * | 2014-10-20 | 2021-04-21 | Elysium Therapeutics Inc | Diversion-resistant opioid formulations |
US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
US10017519B2 (en) | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
US11066366B2 (en) | 2015-09-03 | 2021-07-20 | Allegheny-Singer Research Institute | Hydrophilic fentanyl derivatives |
CN107033154B (zh) * | 2016-02-02 | 2020-02-04 | 上海瀚迈生物医药科技有限公司 | 阿片受体拮抗剂缀合物及其应用 |
EP3416644A4 (en) * | 2016-02-18 | 2020-01-29 | Virginia Commonwealth University | NANOPARTICLE-CONJUGATED SYNTHETIC OPIOID PRODRUGS AND METHOD FOR THE USE THEREOF |
CN108210933B (zh) * | 2016-12-22 | 2021-05-04 | 北京键凯科技股份有限公司 | 一种地佐辛与聚乙二醇的结合物 |
JP7369687B2 (ja) | 2017-07-20 | 2023-10-26 | スーチョウ ランシンダタイ ファーマシューティクス エルティーディー シーオー. | 乱用防止長期作用型徐放性オピオイドプロドラッグ |
SG11202100580UA (en) | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
WO2020205537A1 (en) * | 2019-03-29 | 2020-10-08 | Allegheny Singer Research Institute | Covalent modification and controlled delivery of mu opioid receptor antagonists |
WO2024134619A1 (en) | 2022-12-23 | 2024-06-27 | Sintalica S.R.L. | Non-hallucinogenic tryptamine compounds, preparation, pharmaceutical compositions and uses thereof |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2433883C2 (de) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Verwendung von physiologisch aktiven Polypeptiden |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4864781A (en) * | 1981-06-17 | 1989-09-12 | Emblin Robert T | Multiple panel metal roofing system with overlapping panel edges |
US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
FR2514644A1 (fr) | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4806556A (en) * | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
DK0386644T3 (da) * | 1989-03-10 | 1997-10-13 | Hoffmann La Roche | Reagenser til bestemmelse af lægemidler |
JPH0383914A (ja) * | 1989-08-18 | 1991-04-09 | W R Grace & Co | ドラッグキャリアー |
US5130126A (en) | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5569450A (en) | 1993-03-17 | 1996-10-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
AU2059297A (en) * | 1996-03-12 | 1997-10-01 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
ES2264226T3 (es) * | 1997-12-22 | 2006-12-16 | Euro-Celtique S.A. | Forma farmaceutica de dosificacion oral que comprende una combinacion de un agonista opioide y naltrexona. |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
DK1411075T3 (da) * | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
WO2001046291A1 (en) * | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
PT1255547E (pt) * | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Composições de libertação controlada contendo agonistas e antagonistas opióides |
AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
US20010049375A1 (en) * | 2000-03-15 | 2001-12-06 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
US7829074B2 (en) * | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
JP2004514701A (ja) * | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル,コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
EP1362053B1 (en) | 2001-02-20 | 2007-11-14 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
WO2002092060A1 (en) | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6756354B2 (en) * | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
US20030054030A1 (en) * | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
KR101009309B1 (ko) | 2001-10-18 | 2011-01-18 | 넥타르 테라퓨틱스 | 아편양 길항제의 중합체 공액 |
WO2003037384A2 (en) | 2001-10-29 | 2003-05-08 | Nektar Therapeutics Al, Corporation | Polymer conjugates of protein kinase c inhibitors |
DE60219677T2 (de) | 2001-10-30 | 2008-05-15 | Nektar Therapeutics Al, Corp., Huntsville | Wasserlösliche polymerkonjugate von retinoesäure |
AU2002351388A1 (en) | 2001-12-14 | 2003-06-30 | The University Of Wyoming | Methods and compositions for controlled release of drugs |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
WO2004082620A2 (en) | 2003-03-13 | 2004-09-30 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower the abuse potential and extended duration of action |
US20060182692A1 (en) * | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
ES2733764T3 (es) | 2003-12-16 | 2019-12-02 | Nektar Therapeutics | Método para la preparación de oligo etilenglicol monodisperso |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
CN101466381B (zh) * | 2006-04-21 | 2012-11-14 | 尼克塔治疗公司 | ***酮的立体选择性还原 |
CN101534827A (zh) | 2006-11-07 | 2009-09-16 | 尼克塔治疗亚拉巴马公司 | 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药 |
KR101545874B1 (ko) * | 2007-09-03 | 2015-08-20 | 나노테라퓨틱스, 인코포레이티드 | 난용성 약물의 전달을 위한 입상 조성물 |
KR102612902B1 (ko) | 2016-04-22 | 2023-12-18 | 삼성디스플레이 주식회사 | 투명 전도막 및 이를 포함하는 전자 소자 |
-
2002
- 2002-10-18 KR KR1020097025168A patent/KR101009309B1/ko active IP Right Grant
- 2002-10-18 MX MXPA04003597A patent/MXPA04003597A/es active IP Right Grant
- 2002-10-18 DK DK15172363.2T patent/DK2939696T3/da active
- 2002-10-18 ES ES15172363.2T patent/ES2569262T3/es not_active Expired - Lifetime
- 2002-10-18 EP EP15172363.2A patent/EP2939696B1/en not_active Expired - Lifetime
- 2002-10-18 CA CA2463938A patent/CA2463938C/en not_active Expired - Lifetime
- 2002-10-18 LT LTEP02795531.9T patent/LT1436012T/lt unknown
- 2002-10-18 EP EP10007224A patent/EP2236161A1/en not_active Withdrawn
- 2002-10-18 SI SI200231089T patent/SI1436012T1/en unknown
- 2002-10-18 AU AU2002360284A patent/AU2002360284B2/en active Active
- 2002-10-18 PT PT151723632T patent/PT2939696E/pt unknown
- 2002-10-18 KR KR1020047005735A patent/KR100974842B1/ko active IP Right Grant
- 2002-10-18 US US10/274,296 patent/US7056500B2/en not_active Expired - Lifetime
- 2002-10-18 DK DK02795531.9T patent/DK1436012T3/da active
- 2002-10-18 PT PT2795531T patent/PT1436012T/pt unknown
- 2002-10-18 WO PCT/US2002/033325 patent/WO2003032990A2/en active Application Filing
- 2002-10-18 EP EP02795531.9A patent/EP1436012B1/en not_active Expired - Lifetime
- 2002-10-18 ES ES02795531.9T patent/ES2654819T3/es not_active Expired - Lifetime
- 2002-10-18 JP JP2003535793A patent/JP4814488B2/ja not_active Expired - Lifetime
- 2002-10-18 SI SI200231072A patent/SI2939696T1/sl unknown
-
2006
- 2006-01-17 US US11/332,964 patent/US7662365B2/en not_active Expired - Lifetime
-
2009
- 2009-04-30 JP JP2009111653A patent/JP5570137B2/ja not_active Expired - Lifetime
- 2009-10-06 US US12/574,335 patent/US8349307B2/en not_active Expired - Lifetime
-
2012
- 2012-11-29 US US13/689,640 patent/US8617530B2/en not_active Expired - Lifetime
-
2016
- 2016-03-17 HK HK16103153.9A patent/HK1215171A1/zh not_active IP Right Cessation
-
2018
- 2018-02-12 CY CY20181100170T patent/CY1119906T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1436012T3 (da) | Polymerkonjugater af opioidantagonister | |
AU2002360284A1 (en) | Polymer conjugates of opioid antagonists | |
JP5827123B2 (ja) | 乱用の可能性が低いpeg化オピオイド | |
US7744861B2 (en) | Multi-arm polymer prodrugs | |
JP5877403B2 (ja) | オリゴマー−オピオイドアゴニスト複合体 | |
JP5837491B2 (ja) | オリゴマー−オピオイドアゴニスト抱合体 | |
US20110200550A1 (en) | Multi-Arm Polymeric Alkanoate Conjugates | |
MXPA06003108A (en) | Multi-arm polymer prodrugs |